{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Back Bay Life Science Report","title":"The Evolving Regulatory Framework for Novel Medicines in the EU","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/f93bab9b\"></iframe>","width":"100%","height":180,"duration":1553,"description":"with Peter Bak and Alexander Natz\r\n\r\nBiopharma companies looking to establish a footprint in Europe face country-specific decision-making processes. The health technology assessments (HTAs) in France and Germany, for example, look very different.\r\n\r\nDoes this regional level of thinking make it easier or potentially more difficult to get medicines to market and into the hands of patients who need them?\r\n\r\nIn this episode of Back Bay’s Life Science podcast, Pete Bak is joined by Alexander Natz, Secretary-General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Europe’s principal trade body for companies working in the field of pharma, biotech, and medtech. Based in Brussels, EUCOPE provides expertise across a number of strategic issues such as regulatory paths and pricing and market access.","thumbnail_url":"https://img.transistorcdn.com/W6Lngt-BhnFN8FVt3HSPeq-NUJHgo4jaJncMb2aU6_E/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81NjE3/MTc3NDg3NzgyNTI0/ODE3Y2ViM2Q4OWI5/MDUzMC5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}